SHLP2 (Small Humanin-Like Peptide 2) is the most extensively studied member of the small humanin-like peptide family — a group of six mitochondria-derived peptides encoded by short open reading frames within the 16S rRNA region of the mitochondrial genome. SHLP2 stands out for its prominent metabolic effects: it inhibits adipocyte differentiation, improves insulin sensitivity, and exerts anti-apoptotic protection against amyloid-beta-induced cell death.

Overview

SHLP2 was discovered by Cobb et al. (2016) as part of a comprehensive screen for peptide-coding sORFs within the mitochondrial genome. Among the six SHLPs identified, SHLP2 emerged as the most biologically active, with effects spanning metabolic regulation, cytoprotection, and neuroprotection. SHLP2 inhibits pre-adipocyte differentiation into mature fat cells, enhances insulin receptor signaling, and protects neurons against amyloid-beta-induced apoptosis. Its metabolic profile is particularly notable: SHLP2 improves glucose homeostasis in diabetic animal models and modulates leptin signaling, positioning it at the intersection of obesity, diabetes, and aging research.

Unlike SHLP6 (which is pro-apoptotic), SHLP2 shares the anti-apoptotic orientation of humanin and SHLP1. However, SHLP2 has a stronger metabolic signature than its family members, making it the most promising SHLP for diabetes and obesity-related research.

Mechanism of Action

SHLP2 operates through multiple intersecting mechanisms that collectively improve metabolic function and cell survival.

Adipogenesis Inhibition: SHLP2 suppresses the differentiation of 3T3-L1 pre-adipocytes into mature adipocytes by downregulating PPARγ and C/EBPα, the master transcription factors controlling fat cell maturation. This effect reduces lipid accumulation and alters adipokine secretion profiles, shifting the balance toward insulin-sensitizing adipokines (Kim et al., 2017).

Insulin Sensitization: SHLP2 enhances insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation and downstream PI3K/AKT signaling in skeletal muscle and hepatocytes. This improves glucose transporter 4 (GLUT4) translocation to the plasma membrane, increasing cellular glucose uptake. SHLP2 also suppresses hepatic gluconeogenesis by modulating FOXO1 nuclear exclusion (Cobb et al., 2016).

Anti-Apoptotic Signaling: Like humanin and SHLP1, SHLP2 protects cells from apoptosis by stabilizing mitochondrial membrane potential and reducing cytochrome c release. SHLP2 activates ERK1/2 and STAT3 survival pathways, though its receptor binding partners have not been fully characterized. The peptide reduces caspase-3/7 activation in neurons exposed to amyloid-beta oligomers, preserving cell viability under neurotoxic conditions.

ROS Reduction: SHLP2 reduces mitochondrial reactive oxygen species production by improving electron transport chain efficiency and reducing electron leak at complexes I and III. This antioxidant effect contributes to both its metabolic and cytoprotective properties.

Reconstitution Calculator

Research

Safety Profile

SHLP2 is an endogenous peptide produced naturally by mitochondria. Exogenous administration in rodent models at doses up to 5 mg/kg/day for 28 days has not produced observable adverse effects, including no evidence of hypoglycemia, organ toxicity, or tumor promotion. The anti-adipogenic effects are metabolically favorable and do not cause lipoatrophy at research doses. As with all anti-apoptotic MDPs, the theoretical concern of promoting survival of damaged cells exists but has not been demonstrated experimentally. Notably, observational data linking lower SHLP2 to higher prostate cancer risk suggests the opposite concern — that SHLP2 may be protective against malignancy. No human clinical safety data are available.

Metabolic Studies

Kim et al. (2017) administered SHLP2 at 2 mg/kg IP once daily for 21 days in high-fat diet-induced obese C57BL/6J mice. Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were performed at days 0, 14, and 21. Body composition was assessed by DEXA scanning. In vitro adipogenesis assays used 1–10 micromol/L SHLP2 during the 8-day differentiation protocol for 3T3-L1 pre-adipocytes.

Neuroprotection Studies

In vitro neuroprotection assays typically use 1–10 micromol/L SHLP2 in primary cortical neuron cultures exposed to 5–10 micromol/L amyloid-beta 1-42 oligomers for 24–48 hours. Cell viability is assessed by MTT assay, LDH release, and caspase-3/7 activity. For in vivo neuroprotection, protocols using 2–5 mg/kg IP daily for 14–28 days in APP/PS1 transgenic mice are typical.

Pharmacokinetic Profile